GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-21 and is reviewed periodically as new material appears.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
When asked if Trump supported the Arab leaders' plan, a White House spokesman said that the current Arab plan does not address that Gaza is "currently uninhabitable" for Palestinians to live in to due to the amount of debris and unexploded ordnance, adding that "President Trump stands by his vision to rebuild Gaza free from Hamas. We look forward to further talks to bring peace and prosperity to the region." The US special envoy Steve Witkoff said the plan had "compelling features", was a good first step, and they needed additional discussions. The plan was also endorsed by the Organisation of Islamic Cooperation and several European countries. On 12 March, Arab foreign ministers confirmed continuous consultations on Egypt's plan with the US special envoy.
=== Post-translational modifications === EPCIP has a myristoylation site from amino acid 26–31. It has a sumoylation site from amino acid 132–135. Additionally, it has a nuclear export signal from amino acid 98-104.
=== Transfer RNA === During activation, the tRNA functions as an adaptor molecule, as posited by Francis Crick’s adaptor hypothesis. That is, the tRNA binds at one end to the specific amino acid of interest, and at the other end to the mRNA codon sequence. The tRNA molecule effectively acts as an intermediary between the two, enabling translation of the genetic code to an amino acid sequence.
The fur is soft, with dense underfur and long, coarse, thick guard hairs. The fur is not as shaggy or coarse as that of brown bears. American black bear skins can be distinguished from those of Asian black bears by the lack of a white blaze on the chest and hairier footpads. Despite their name, black bears show a great deal of color variation. Individual coat colors can range from white, blonde, cinnamon, light brown or dark chocolate brown to jet black, with many intermediate variations existing. Silvery-gray American black bears with a blue luster (found mostly on the flanks) occur along a portion of coastal Alaska and British Columbia. White to cream-colored American black bears occur in the coastal islands and the adjacent mainland of southwestern British Columbia. Albino individuals have also been recorded. Black coats tend to predominate in humid areas, such as Maine, New England, New York, Tennessee, Michigan and western Washington. Approximately 70% of all American black bears are black, though only 50% in the Rocky Mountains are black. Many in northwestern North America are cinnamon, blonde or light brown in color and thus may sometimes be mistaken for grizzly bears. Grizzly (and other types of brown) bears can be distinguished by their shoulder hump, larger size and broader, more concave skull. In his book The Great Bear Almanac, Gary Brown summarized the predominance of black or brown/blonde specimens by location:
== Applications == Estimation of the size of DNA molecules following restriction enzyme digestion, e.g. in restriction mapping of cloned DNA. Analysis of PCR products, e.g. in molecular genetic diagnosis or genetic fingerprinting Separation of restricted genomic DNA prior to Southern transfer, or of RNA prior to Northern transfer. Gel electrophoresis is used in forensics, molecular biology, genetics, microbiology and biochemistry. The results can be analyzed quantitatively by visualizing the gel with UV light and a gel imaging device. The image is recorded with a computer-operated camera, and the intensity of the band or spot of interest is measured and compared against standard or markers loaded on the same gel. The measurement and analysis are mostly done with specialized software. Depending on the type of analysis being performed, other techniques are often implemented in conjunction with the results of gel electrophoresis, providing a wide range of field-specific applications.
Sources: en.wikipedia.org
Ovarian cysts such as in polyendocrine metabolic ovarian syndrome (PMOS), the most common cause in women. Adrenal gland tumors, adrenocortical adenomas, and adrenocortical carcinoma, as well as adrenal hyperplasia due to pituitary adenomas (as in Cushing's disease). Inborn errors of steroid metabolism such as in congenital adrenal hyperplasia, most commonly caused by 21-hydroxylase deficiency. Acromegaly and gigantism (growth hormone and IGF-1 excess), usually due to pituitary tumors.
In 1946, Freeman performed this procedure for the first time on a patient, who was subdued before the operation with electroshock treatment. The transorbital lobotomy procedure, which Freeman performed very quickly, sometimes in less than 10 minutes, was used on many patients with relatively minor mental disorders that Freeman believed did not warrant traditional lobotomy surgery, in which the skull itself was opened. A large proportion of such lobotomized patients exhibited reduced tension or agitation. Many also showed other effects, such as apathy, passivity, lack of initiative, poor concentration, and a generally decreased depth and intensity of their emotional response to life. Some died as a result of the procedure. However, those effects were not widely reported in the 1940s, and at that time, the long-term effects were largely unknown. Because the procedure met with seemingly widespread success, Moniz was awarded the 1949 Nobel Prize for Physiology or Medicine (along with Swiss physiologist Walter Rudolf Hess). Lobotomies were performed on a wide scale during the 1940s; Freeman himself performed or supervised more than 3,500 lobotomies by the late 1960s. Freeman performed his first transorbital lobotomy on Ellen Ionesco, a woman who suffered from bouts of manic depression and suicidal ideation. Freeman utilized media coverage and penned editorials for numerous interviews promoting the procedure and achieving accolades for his work in psychiatric care.
Higher temperatures accelerate germination, with 23 °C (73 °F) promoting faster colony formation than 19 °C (66 °F). Light exposure is unnecessary for early fungal growth—cultures in darkness develop healthier, more extensive mycelial networks. Developing mycobiont morphology provides insights into early symbiosis. In vitro, X. parietina forms septate, branched hyphae, which later develop into lobed structures, resembling early lichen thalli. Scanning electron microscopy reveals a dense, interwoven hyphal network, potentially facilitating photobiont interactions during natural lichenization. These adaptations support X. parietina's regenerative ability and symbiotic establishment across varied environments. Although X. parietina lacks specialized vegetative propagules, it has a regenerative capacity that enhances its ecological success. Older, apothecia-covered thalli detach along drought-induced cracks, while younger margins remain attached. When fragments land on suitable substrates, they regenerate new lobes along wound margins, acting as natural propagules. Field studies show a 150% laminal size increase in just 13 months in regenerating thalli. In a five-year experiment, X. parietina maintained 50% substrate coverage, despite losing 90% of its initial thallus area, as regrowth compensated for these losses. Total turnover (growth + loss) exceeded 170%, highlighting its dynamic life cycle.
=== Legal status === Icotrokinra was approved for medical use in the United States in March 2026. In July 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Icotyde, intended for the treatment of plaque psoriasis in adults and adolescents. The applicant for this medicinal product is Janssen-Cilag International N.V.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.